John Heymach
约翰·海马赫
MD, PhD
Chair, Department of Thoracic/Head and Neck Medical Oncology胸部/头颈部肿瘤内科主任
👥Biography 个人简介
John Heymach leads thoracic oncology research at MD Anderson, focusing on EGFR- and ALK-driven NSCLC. He has driven clinical development of osimertinib, amivantamab, and novel combinations that have transformed treatment of oncogene-addicted lung cancers.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
EGFR-Targeted Therapy
Led pivotal trials evaluating osimertinib and next-generation EGFR inhibitors, establishing new standards of care for EGFR-mutant NSCLC in first-line and post-progression settings.
Resistance Mechanisms
Characterized molecular mechanisms of acquired resistance to EGFR/ALK inhibitors, enabling rational design of combination strategies to overcome resistance in thoracic oncology.
Representative Works 代表性著作
Osimertinib in previously untreated EGFR-mutated advanced non-small-cell lung cancer
New England Journal of Medicine (2018)
FLAURA trial demonstrating superior PFS and CNS activity of osimertinib vs. first-gen EGFR TKIs, changing first-line NSCLC standard of care.
Amivantamab plus lazertinib in EGFR-mutant lung cancer
New England Journal of Medicine (2024)
Mariposa trial establishing bispecific antibody plus EGFR TKI combination as a new first-line option for EGFR-mutant NSCLC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Lecia V. Sequist
Massachusetts General Hospital / Harvard Medical School
Mark G. Kris
Memorial Sloan Kettering Cancer Center
Geoffrey R. Oxnard
Foundation Medicine / Harvard Medical School
Alice T. Shaw
Novartis Institutes for BioMedical Research / Massachusetts General Hospital
关注 约翰·海马赫 的研究动态
Follow John Heymach's research updates
留下邮箱，当我们发布与 John Heymach（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment